Side Area Logo
Welcome to unde omnis iste natus error sit voluptatem accusantium
Keep conected


Press Releases

Discovery Labs to Announce Results from AEROSURF® Phase 2a Expansion Clinical Trial
Conference Call Scheduled for Thursday, November 12, 2015 at 8:00 a.m. Eastern Time

WARRINGTON, Pa., Nov. 6, 2015 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, will announce top-line results from its AEROSURF® Phase 2a expansion clinical trial in premature infants 29 – 34 gestational age with respiratory distress syndrome (RDS) on Thursday, November 12, 2015 at approximately 7:00 a.m. EST.

Discovery Labs management will host a conference call and live webcast, including a slide presentation, on Thursday, November 12, 2015 at 8:00 a.m. EST to review and discuss the results of the trial. The live webcast and archive of the conference call can be accessed at

For "listen-only" participants and those who wish to take part in the question and answer portion of the call, dial (888) 346-0767 (domestic) or (412) 902-4251 (international). After placing the call, request to be joined into the Discovery Labs conference call.  A replay of the conference call will be accessible one hour after completion through November 20, 2015 by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and referencing conference ID number 10076116.

About Discovery Labs
Discovery Laboratories, Inc. is a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases.  Surfactants are produced naturally in the lung and are essential for normal respiratory function and survival.  If surfactant deficiency or degradation occurs, the air sacs in the lungs can collapse, resulting in severe respiratory diseases and disorders.  Discovery Labs' technology platform includes a novel synthetic peptide-containing (KL4) surfactant, that is structurally similar to pulmonary surfactant, and proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant.  Discovery Labs believes that its proprietary technology platform makes it possible, for the first time, to develop a significant pipeline of aerosolized surfactant products to address a variety of respiratory diseases for which there frequently are few or no approved therapies.

For more information, please visit the Company's website at

Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.  Examples of such risks and uncertainties are described in Discovery Labs' filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Except as otherwise required by law, Discovery Labs undertakes no obligation to update or revise any forward-looking statements.

SOURCE Discovery Laboratories, Inc.

For further information: John Tattory, Senior Vice President & Chief Financial Officer: 215.488.9418 or

print email rss